Artisan Partners Limited Partnership Has $76.17 Million Position in Veracyte, Inc. (NASDAQ:VCYT)

Artisan Partners Limited Partnership lowered its position in Veracyte, Inc. (NASDAQ:VCYTFree Report) by 3.8% during the 3rd quarter, Holdings Channel reports. The fund owned 3,411,122 shares of the biotechnology company’s stock after selling 133,700 shares during the period. Artisan Partners Limited Partnership’s holdings in Veracyte were worth $76,170,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in shares of Veracyte in the first quarter valued at approximately $27,000. Point72 Hong Kong Ltd bought a new position in shares of Veracyte in the first quarter valued at approximately $33,000. International Assets Investment Management LLC bought a new position in shares of Veracyte in the third quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Veracyte by 96.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,862 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 913 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Veracyte by 533.0% in the third quarter. CWM LLC now owns 2,146 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,807 shares in the last quarter.

Veracyte Price Performance

NASDAQ:VCYT opened at $25.57 on Friday. The business has a fifty day simple moving average of $26.58 and a two-hundred day simple moving average of $24.99. Veracyte, Inc. has a 1 year low of $19.52 and a 1 year high of $30.52.

Veracyte (NASDAQ:VCYTGet Free Report) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.13. Veracyte had a negative return on equity of 2.09% and a negative net margin of 14.56%. The business had revenue of $90.11 million during the quarter, compared to the consensus estimate of $84.78 million. On average, equities analysts predict that Veracyte, Inc. will post -0.32 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on VCYT. William Blair reaffirmed an “outperform” rating on shares of Veracyte in a research report on Wednesday, November 8th. Morgan Stanley decreased their price target on Veracyte from $23.00 to $22.00 and set an “underweight” rating for the company in a research report on Friday, November 10th. The Goldman Sachs Group decreased their price target on Veracyte from $37.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, October 20th. Finally, Needham & Company LLC decreased their price target on Veracyte from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Veracyte currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Read Our Latest Analysis on Veracyte

Veracyte Company Profile

(Free Report)

Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.

Recommended Stories

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYTFree Report).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.